Parathyroid carcinoma: molecular therapeutic targets

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Parathyroid carcinoma (PC) is a rare malignancy (<1% of primary hyperparathyroidism) with aggressive behavior, high metastatic potential, and poor prognosis.
• PC is often sporadic but can be associated with congenital endocrine syndromes.
• The molecular pathogenesis of PC is complex, involving multiple genetic and epigenetic factors that distinguish it from benign parathyroid adenoma (PA).

Purpose of the Study:

• To review the molecular pathogenetic aspects of parathyroid carcinoma.
• To summarize the current therapeutic strategies for parathyroid carcinoma.
• To highlight the need for targeted therapies based on molecular profiling.

Main Methods:

• Review of existing literature on the molecular pathogenesis of PC.
• Analysis of genetic and epigenetic alterations in PC.
• Evaluation of current treatment modalities and their limitations.

Main Results:

• Germline mutations in the CDC73 tumor suppressor gene are associated with congenital forms of PC (HPT-JT, FIPH).
• The molecular drivers of sporadic PC are diverse and not fully elucidated.
• Surgical resection is the primary treatment but often ineffective for advanced/metastatic disease, with high recurrence rates.

Conclusions:

• Targeted medical therapies for surgically untreatable PC are urgently needed.
• Characterizing genetic and epigenetic alterations is essential for tailoring treatments to individual patients.
• Further research into the molecular landscape of PC will guide the development of novel therapeutic strategies.